AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33230964 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 599
Study 33230964 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions combined
Number of subjects: 599
Study 35832798 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhomboid Intercostal Block (RIB)
Number of subjects: 90
Study 35832798 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESP)
Number of subjects: 90
Study 35832798 — intervention group
Group type: COMPARATOR
Intervention: Serratus Plane Block (SAB)
Number of subjects: 90
Study 35832798 — intervention group
Group type: EXPERIMENTAL
Intervention: RIB
Number of subjects: 90
Study 35832798 — intervention group
Group type: EXPERIMENTAL
Intervention: ESP
Number of subjects: 90
Study 35832798 — intervention group
Group type: COMPARATOR
Intervention: SAB
Number of subjects: 90
Study 35832798 — intervention group
Group type: EXPERIMENTAL
Intervention: RIB and ESP
Number of subjects: 90
Study 35832798 — intervention group
Group type: COMPARATOR
Intervention: RIB, ESP, and SAB
Number of subjects: 90
Study 33857018 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk PL-enriched cream cheese (0, 3, or 5 g of milk PL)
Number of subjects: 58
Study 34126506 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl-21 °C
Number of subjects: 92
Study 34126506 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl-60 °C
Number of subjects: 92
Study 34126506 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-80 °C
Number of subjects: 92
Study 34126506 — intervention group
Group type: COMPARATOR
Intervention: Saline-21 °C
Number of subjects: 92
Study 34126506 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl-80 °C
Number of subjects: 92
Study 35411169 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD) with good adherence over 12 weeks (KIDMED 8-point score)
Number of subjects: 100
Study 35411169 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (KIDMED score ≤7 points)
Number of subjects: 100
Study 34578969 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG)
Number of subjects: 63
Study 33216975 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation (SCT)
Number of subjects: 60
Study 33216975 — intervention group
Group type: COMPARATOR
Intervention: Standard-care (chronic transfusion for 1-year minimum)
Number of subjects: 60
Study 35723240 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 1000
Study 33545784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided indwelling cannula needle
Number of subjects: 61
Study 33545784 — intervention group
Group type: COMPARATOR
Intervention: Blind indwelling cannula needle
Number of subjects: 61
Study 33120774 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple injection (TI group, n=34)
Number of subjects: 68
Study 33120774 — intervention group
Group type: COMPARATOR
Intervention: Single injection (SI group, n=34)
Number of subjects: 68
Study 35442220 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Carbohydrate Diet (SCD)
Number of subjects: 54
Study 35442220 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Specific Carbohydrate Diet (MSCD)
Number of subjects: 54
Study 35442220 — intervention group
Group type: COMPARATOR
Intervention: Usual Diet (UD)
Number of subjects: 54
Study 36075249 — intervention group
Group type: EXPERIMENTAL
Intervention: ABX464 100 mg
Number of subjects: 254
Study 36075249 — intervention group
Group type: EXPERIMENTAL
Intervention: ABX464 50 mg
Number of subjects: 254
Study 36075249 — intervention group
Group type: EXPERIMENTAL
Intervention: ABX464 25 mg
Number of subjects: 254
Study 36075249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 33820822 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg) plus decitabine (10 mg/day, days 1-5) every 3 weeks
Number of subjects: 61
Study 33820822 — intervention group
Group type: COMPARATOR
Intervention: Camrelizumab (200 mg) monotherapy
Number of subjects: 61
Study 33405297 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% ICR to 160% ICR
Number of subjects: 27
Study 33405297 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing insulin dose (100% to 160% ICR)
Number of subjects: 27
Study 35982198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine bolus of 1.5 mg/kg over 5 min followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively
Number of subjects: 58
Study 35982198 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 58
Study 35982198 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine administration
Number of subjects: 58
Study 32673250 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid interactive voice response survey
Number of subjects: 1766
Study 32673250 — intervention group
Group type: COMPARATOR
Intervention: Computer-assisted telephone interview
Number of subjects: 1766
Study 36182236 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention
Number of subjects: 1269
Study 36182236 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week open-group behavioural programme
Number of subjects: 1269
Study 36182236 — intervention group
Group type: EXPERIMENTAL
Intervention: 52-week open-group behavioural programme
Number of subjects: 1269
Study 36182236 — intervention group
Group type: COMPARATOR
Intervention: 52-week programme vs. brief intervention
Number of subjects: 1269
Study 36182236 — intervention group
Group type: EXPERIMENTAL
Intervention: 52-week programme vs. 12-week programme
Number of subjects: 1269
Study 36182236 — intervention group
Group type: COMPARATOR
Intervention: 12-week programme vs. brief intervention
Number of subjects: 1269
Study 36182236 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week programme
Number of subjects: 1269
Study 36182236 — intervention group
Group type: EXPERIMENTAL
Intervention: 52-week programme
Number of subjects: 1269
Study 32936055 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing literacy interventions
Number of subjects: 18
Study 32936055 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 18
Study 33186492 — intervention group
Group type: COMPARATOR
Intervention: Polypill (40 mg simvastatin, 100 mg atenolol, 25 mg hydrochlorothiazide, 10 mg ramipril)
Number of subjects: 5713
Study 33186492 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (75 mg)
Number of subjects: 5713
Study 33186492 — intervention group
Group type: COMPARATOR
Intervention: Polypill plus Aspirin
Number of subjects: 5713
Study 33186492 — intervention group
Group type: COMPARATOR
Intervention: Polypill
Number of subjects: 5713
Study 33106446 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg, 20 min before surgery)
Number of subjects: 48
Study 33106446 — intervention group
Group type: COMPARATOR
Intervention: Psychological preparation (booklet and explanation by anaesthesia resident)
Number of subjects: 48
Study 36424542 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1000 mg PO once
Number of subjects: 0
Study 36424542 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin 500 mg PO once, followed by Azithromycin 250 mg PO daily for four days
Number of subjects: 0
Study 33693468 — intervention group
Group type: EXPERIMENTAL
Intervention: Provitamin A carotenoid-biofortified maize (∼315 µg RE/d to mothers and ∼55 µg RE/d to infants)
Number of subjects: 255
Study 33693468 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate-fortified maize (∼315 µg RE/d to mothers and ∼55 µg RE/d to infants)
Number of subjects: 255
Study 33693468 — intervention group
Group type: COMPARATOR
Intervention: Conventional maize (0 µg RE/d)
Number of subjects: 255
Study 32410922 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Weight (BW)
Number of subjects: 327
Study 32410922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean Body Weight (LBW)
Number of subjects: 327
Study 32410922 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Output (CO)
Number of subjects: 327
Study 35294272 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 203
Study 35294272 — intervention group
Group type: COMPARATOR
Intervention: Blood Glucose Monitoring (BGM) followed by Continuous Glucose Monitoring (CGM)
Number of subjects: 203
Study 32255565 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting hospital-acquired pressure injuries (HAPIs)
Number of subjects: 2341
Study 35641112 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 188
Study 34105265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole orally disintegrating tablets (10 mg) in fasting state
Number of subjects: 60
Study 34105265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole orally disintegrating tablets (10 mg) in fed state
Number of subjects: 60
Study 34105265 — intervention group
Group type: COMPARATOR
Intervention: Test and reference formulations (both fasting and fed conditions)
Number of subjects: 60
Study 34105265 — intervention group
Group type: COMPARATOR
Intervention: Test and reference formulations
Number of subjects: 60
Study 35909369 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab or Adalimumab
Number of subjects: 611
Study 34936830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine (8 mg)
Number of subjects: 9
Study 33075170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual wafer (25 mg CBD)
Number of subjects: 12
Study 33075170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual wafer (50 mg CBD)
Number of subjects: 12
Study 33075170 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil solution (50 mg CBD)
Number of subjects: 12
Study 33075170 — intervention group
Group type: COMPARATOR
Intervention: Nabiximols oromucosal spray (20 mg CBD, 21.6 mg THC)
Number of subjects: 12
Study 33075170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual wafer (50 mg CBD, multiple doses)
Number of subjects: 12
Study 33075170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual wafer and oil solution
Number of subjects: 12
Study 32590831 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-axis in-plane approach
Number of subjects: 97
Study 32590831 — intervention group
Group type: COMPARATOR
Intervention: Short-axis out-of-plane approach
Number of subjects: 97
Study 36087572 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics supplementation
Number of subjects: 46
Study 33030035 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 78
Study 33030035 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injection
Number of subjects: 78
Study 33030035 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic injection (control group)
Number of subjects: 78
Study 32407460 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose colchicine (0.5 mg once daily)
Number of subjects: 4745
Study 32407460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4745
Study 32319740 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronomodulated Irinotecan (morning delivery)
Number of subjects: 193
Study 32319740 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronomodulated Irinotecan (afternoon delivery)
Number of subjects: 193
Study 35526293 — intervention group
Group type: EXPERIMENTAL
Intervention: PragmaCom intervention
Number of subjects: 0
Study 35526293 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study 33884972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 31
Study 33884972 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-propofol combination
Number of subjects: 31
Study 35660971 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily (EXP2–3A)
Number of subjects: 176
Study 35660971 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily (EXP3B–5)
Number of subjects: 176
Study 35660971 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily
Number of subjects: 176
Study 34991489 — intervention group
Group type: EXPERIMENTAL
Intervention: M-ESD group (using multi-loop traction device)
Number of subjects: 34
Study 34991489 — intervention group
Group type: COMPARATOR
Intervention: C-ESD group (conventional ESD)
Number of subjects: 34
Study 34991489 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 34
Study 34991489 — intervention group
Group type: EXPERIMENTAL
Intervention: MLTD
Number of subjects: 34
Study 32035704 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically managed patients with MRI-verified soft tissue injuries
Number of subjects: 56
Study 32035704 — intervention group
Group type: COMPARATOR
Intervention: Surgically managed patients without MRI-verified soft tissue injuries
Number of subjects: 56
Study 33573895 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwritten rehearsal of core and custom consent items
Number of subjects: 90
Study 33573895 — intervention group
Group type: COMPARATOR
Intervention: Audiovisual presentation (Group B)
Number of subjects: 90
Study 33573895 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall anxiety levels
Number of subjects: 90
Study 32294881 — intervention group
Group type: EXPERIMENTAL
Intervention: Food hygiene intervention (food hygiene + handwashing)
Number of subjects: 0
Study 32294881 — intervention group
Group type: EXPERIMENTAL
Intervention: Food hygiene and WASH intervention (food hygiene + handwashing + faeces management + water management)
Number of subjects: 0
Study 32294881 — intervention group
Group type: COMPARATOR
Intervention: Control group (food hygiene and WASH intervention)
Number of subjects: 0
Study 34923257 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimalist shoes
Number of subjects: 70
Study 34923257 — intervention group
Group type: COMPARATOR
Intervention: Standard shoes (control)
Number of subjects: 70
Study 33068751 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TNS treatment for 4 weeks
Number of subjects: 51
Study 33068751 — intervention group
Group type: COMPARATOR
Intervention: Sham TNS treatment for 4 weeks (control)
Number of subjects: 51
Study 32576214 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional oversight in the Notice version
Number of subjects: 89
Study 32576214 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and adjusting practices
Number of subjects: 89
Study 32576214 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifying adaptations while maintaining core components
Number of subjects: 89
Study 32576214 — intervention group
Group type: EXPERIMENTAL
Intervention: Conducting initial training
Number of subjects: 89
Study 32576214 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularly sharing lessons learned
Number of subjects: 89
Study 32576214 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≤ 35 years
Number of subjects: 89
Study 32576214 — intervention group
Group type: EXPERIMENTAL
Intervention: < 5 years in primary role
Number of subjects: 89
Study 32576214 — intervention group
Group type: EXPERIMENTAL
Intervention: More prior academic detailing around pain and opioid safety
Number of subjects: 89
Study 35738968 — intervention group
Group type: EXPERIMENTAL
Intervention: S-268019-b
Number of subjects: 204
Study 35738968 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2
Number of subjects: 204
Study 35738968 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 204
Study 34903257 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention combining psychological treatment for depression and a parenting programme (10 sessions: 4 antenatal and 6 postnatal sessions, plus a booster session at 16 months)
Number of subjects: 528
Study 34903257 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Standard of Care (ESoC: 2 antenatal and 2 postnatal counselling support and advice telephone calls)
Number of subjects: 528
Study 35433421 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab combined with neoadjuvant chemotherapy (neoCT)
Number of subjects: 342
Study 35433421 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy (neoCRT)
Number of subjects: 342
Study 33883758 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin traction
Number of subjects: 86
Study 33883758 — intervention group
Group type: COMPARATOR
Intervention: Skeletal traction
Number of subjects: 86
Study 36131595 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 0
Study 36131595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33542474 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal microvascular fractal dimension
Number of subjects: 628
Study 33142521 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterols (25 mg/kg)
Number of subjects: 360
Study 33142521 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (200 mg/kg oxytetracycline calcium and 250 mg/kg nosiheptide)
Number of subjects: 360
Study 33142521 — intervention group
Group type: COMPARATOR
Intervention: Control (basal diet)
Number of subjects: 360
Study 36484304 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Number of subjects: 302
Study 33999494 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of diversion >328 days
Number of subjects: 173
Study 33999494 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of diversion
Number of subjects: 173
Study 33999494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric intubation
Number of subjects: 173
Study 33999494 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 173
Study 32799042 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 108
Study 32799042 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 108
Study 36420938 — intervention group
Group type: EXPERIMENTAL
Intervention: OL-HDF (FxCordiax HDF 800TM)
Number of subjects: 14
Study 36420938 — intervention group
Group type: COMPARATOR
Intervention: Theranova 500®
Number of subjects: 14
Study 36420938 — intervention group
Group type: COMPARATOR
Intervention: Elisio 21HXTM
Number of subjects: 14
Study 34459426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-health CIMT (Tele-AutoCITE)
Number of subjects: 24
Study 34459426 — intervention group
Group type: COMPARATOR
Intervention: In-lab CIMT
Number of subjects: 24
Study 34245292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic non-immersive virtual reality exercise programme
Number of subjects: 56
Study 35126309 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum K50 (LPK)
Number of subjects: 81
Study 35126309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 32543211 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 110
Study 32543211 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 110
Study 35596529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous perampanel (12 mg) administered via 30- or 60-minute infusion
Number of subjects: 48
Study 35596529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous perampanel (12 mg)
Number of subjects: 48
Study 35596529 — intervention group
Group type: COMPARATOR
Intervention: Intravenous perampanel
Number of subjects: 48
Study 34510846 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 275
Study 34510846 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-Fowler position
Number of subjects: 275
Study 34510846 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 275
Study 35462428 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 942
Study 35462428 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 942
Study 35462428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 942
Study 32088207 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 91
Study 32088207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 34972488 — intervention group
Group type: EXPERIMENTAL
Intervention: SHRed Injuries Basketball program (10-minute program with 13 exercises)
Number of subjects: 502
Study 34972488 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised SHRed Injuries Basketball program
Number of subjects: 502
Study 34972488 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised SHRed Injuries Basketball program
Number of subjects: 502
Study 34972488 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-practice warm-up (control group)
Number of subjects: 502
Study 32034876 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on organ slicing (experimental group)
Number of subjects: 182
Study 32034876 — intervention group
Group type: COMPARATOR
Intervention: Prosection mode (control group)
Number of subjects: 182
Study 36415902 — intervention group
Group type: EXPERIMENTAL
Intervention: Light exposure stimulus at varying intensities (5 to 5000 lux) for 1 hour before bedtime
Number of subjects: 33
Study 36415902 — intervention group
Group type: EXPERIMENTAL
Intervention: Light exposure stimulus
Number of subjects: 33
Study 33485088 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasound showing presence of a halo
Number of subjects: 81
Study 33485088 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasound showing occlusion of the TA
Number of subjects: 81
Study 33485088 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pain
Number of subjects: 81
Study 33485088 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual disturbances
Number of subjects: 81
Study 33485088 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between duplex findings and biopsy
Number of subjects: 81
Study 32173214 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education and counseling intervention (3 walking and face-to-face group sessions plus text messages)
Number of subjects: 164
Study 33389521 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg dexamethasone phosphate (DEX-P) administered orally (PO)
Number of subjects: 48
Study 33389521 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg betamethasone phosphate (BET-P) administered orally (PO)
Number of subjects: 48